In this study, we developed a new strategy that combined the B16F10/GPI-IL-21 vaccination with the TGF-β1 knockdown in the B16F10 cells and with the miR200c agomir injection to elicit immune responses against the B16F10 melanoma and to inhibit tumor metastases in a murine model. Here, TGFB1 is linked to melanoma.